Drug firm Zydus Cadila today said the US health regulator has approved the group's plans to initiate phase II clinical trials of Saroglitazar Magnesium in patients suffering from a certain liver disease. "The United States Food and Drug Administration (USFDA) ... Business Standard, 1 month ago
Zydus Cadila gets USFDA nod to market muscle relaxant in US - Business Standard, 2 weeks ago
Zydus Cadila receives USFDA nod to market fluconazole tablets - Business Standard, 1 month ago
Cadila Healthcare Limited shares tanked to Rs 407.25, losing about 7% in the process, after the company said USFDA issued three observations after inspecting the company's facility at Baddi. The stock recovered swiftly from that level and is currently trading ...Sify, 3 weeks ago
Drug firm Cadila Healthcare today said it has settled all outstanding patent litigation related to Qudexy XR (topiramate) extended-release capsules with US-based Upsher-Smith Laboratories, Inc. The company and its subsidiary, Zydus Pharmaceuticals (USA) Inc, ...Business Standard, 2 months ago
The market is quite sluggish today with investors largely treading cautiously, looking ahead to the US President Donald Trump's speech on Tuesday, which is likely to spell out some elements of his plans to cut taxes. Activity is quite stock specific with ...Sify, 4 weeks ago
Posted by Equitymaster Global markets ended the week on a dull note with most of the markets ending flat or in the negative territory. Brazil's and China's indices were the only ones which ended the week on a positive note, with gains of 0.5% and 0.3% ...Equitymaster.com, 2 months ago
on your WebpageAdd Widget >Get your members hooked!